IL17A and Crohn disease: Moreover, ileal biopsies obtained from patients with SpA who developed Crohn’s disease while on anti-IL-17 therapy showed an expansion of type 2 immune cells producing IL-17/IL-25 and expansion of type-2 innate lymphoid cells (ILC2s), compared with pre-IL-17i treatment levels.[26]